Severe adverse drug reactions/hyperhydrosis induced by Sunitinib misuse in a nephrectomy patient:A case Report

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor licensed for the treatment of renal cell carcinoma both in the first line and post immunotherapy setting.However,no usage indated that Sunitinib could used as a preventative measure for renal cell carcinoma.In this case report,we describe a 48-years old patient who has developed renal cell carcinoma,and recovered well after the laparoscopic radical nephrectomy.There should be no necessary for the patient to take Sunitinib after the operation,but he took it as a preventative measure.The patient suffered severe hyperhidrosis side-effects from the treatment,which was quite rare.
Sunitinib Hyperhydrosis Kidney cancer Drug misuse
Xin Li YueFeng Rao HongYu Yang
The first affiliated hospital,Zhejiang University
国内会议
重庆
英文
1-4
2017-06-16(万方平台首次上网日期,不代表论文的发表时间)